Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/08/2005US6962913 Benzo-1,4-diazepin-2-ones as inhibitors of Aβ protein production
11/08/2005US6962912 Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
11/08/2005US6962911 Treatment of impotence, sexual dysfunction in female, stable, unstable and variant angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis
11/08/2005US6962910 ((2,2'-bipyridine)2Os(2,3-bis(2-pyridyl)pyrazine)RhCl2(2,3-bis(2 -pyridyl) pyrazine) Os(2,2'-bipyridine)2)(X)5, where X is a counterion selected from PF6-, CL-, BR-, CF3SO3- and BF4- a supramolecular metal complex; photodynamic therapy
11/08/2005US6962909 Treatment of neovascularization disorders with squalimine
11/08/2005US6962908 Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
11/08/2005US6962900 Pharmaceutical being used for treating HIV infection, the composition and uses thereof
11/08/2005US6962899 Administerinbg N acyl-amino acid such as N-acetyl-phenylalanyl-acrylic acid
11/08/2005US6962801 Protein for blocking platelet adhesion
11/08/2005US6962792 cyclin-dependent kinase 4 (CDK4); useful in treatment of tumours and other hyperproliferative disorders
11/08/2005US6962791 Preventing, inhibiting or enhancing binding between pilus subunit and periplasmic molecular chaperone in pilus-forming bacteria, periplasmic molecular chaperone being one that binds pilus subunits during transport of subunits
11/08/2005US6962784 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
11/08/2005US6962720 Triterpene compositions and methods for use thereof
11/08/2005US6962719 includes American ginseng or extract obtained by extracting with water or ethanol aqueous solution, and then ultrafiltrating, dialyzing, precipitating with ethanol, or performing reverse phase chromatography
11/08/2005US6962717 Pharmaceutical compositions
11/08/2005US6962714 Critical fluid antimicrobial compositions and their use and generation
11/08/2005US6962712 Cosmetic or dermatological composition comprising of a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent
11/08/2005US6962710 Compounds and methods for immunotherapy and diagnosis of tuberculosis
11/08/2005US6962691 Topical spray compositions
11/08/2005CA2382599C Flushable disposable polymeric products
11/08/2005CA2319272C Novel aminoalkanesulphonic, -phosphonic and -phosphinic acid derivatives, their preparation and their use as medicaments
11/08/2005CA2310950C An efficacious dosage regiment of galantamine that reduces side effects
11/08/2005CA2297294C Phosphonomethoxymethylpurine/pyrimidine derivatives
11/08/2005CA2269501C Pellets having a core coated with an antifungal and a polymer
11/08/2005CA2256085C Association of procysteine with a polyol
11/08/2005CA2251690C New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
11/08/2005CA2247020C Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
11/08/2005CA2221255C Use of selegiline to treat hearing loss in mammals
11/08/2005CA2195677C Endothelin antagonists
11/08/2005CA2193405C Eyewash intended in particular for the treatment of the dry eye syndrome
11/08/2005CA2176392C Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
11/08/2005CA2157288C Methods and compositions for inhibition of angiogenesis
11/08/2005CA2155104C Heterocyclic-substituted alkyl amide acat inhibitors
11/08/2005CA2149753C Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
11/08/2005CA2123691C Antiviral compositions and method for their use
11/07/2005CA2506492A1 Irrigation solution for use in ultrasound energy assisted surgery
11/06/2005CA2505836A1 Topical brimonidine tartrate formulations that lack chlorine dioxide
11/03/2005WO2005103291A1 Novel ligand of g-protein-conjugated receptor protein and use thereof
11/03/2005WO2005103288A1 Screening method
11/03/2005WO2005103255A1 Formylpeptide receptor (fpr) as a target for anti-malignant glioma therapy
11/03/2005WO2005103089A1 Fish-origin chondroitin sulfate/dermatan sulfate hybrid chain
11/03/2005WO2005103085A1 A diabody which specifically binds streptococcus surface antigen i/ii and methods of use thereof
11/03/2005WO2005103065A1 Anthracycline derivatives
11/03/2005WO2005103064A1 Novel sugar chain-supported carbosilane dendrimer
11/03/2005WO2005103058A1 Polymorphic forms of methyl (+) - (s) -alpha- (2-chlorophenyl) -6, 7-dihydrothieno `3,2-c!pyridine-584h) acetate hydrobromide, clopidrogel hydrobromide
11/03/2005WO2005103055A1 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
11/03/2005WO2005103054A2 Bridged piperazine and piperidine derivatives as ccri antagonists
11/03/2005WO2005103052A1 Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
11/03/2005WO2005103051A1 Inhibitors of the hiv integrase enzyme
11/03/2005WO2005103049A1 Imidazopyridine compound
11/03/2005WO2005103042A1 Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
11/03/2005WO2005103039A1 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
11/03/2005WO2005103037A2 Selected cgrp antagonists, methods for the production thereof, and use thereof as medicaments
11/03/2005WO2005103034A1 Novel piperidine substituted diaminothiazoles
11/03/2005WO2005103030A1 1,4-di substituted benzene compounds, process for preparing the same and use thereof
11/03/2005WO2005103028A1 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
11/03/2005WO2005103022A1 Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
11/03/2005WO2005103017A1 Method for increasing specific surface area of slightly soluble drug
11/03/2005WO2005103015A1 Triazine compounds and their analogs, compositions, and methods
11/03/2005WO2005103014A1 2,4-dioxo-5-(2-hydroxy-3,5-dichloro-benzylidene)imino-1,3-pyrimidine salts
11/03/2005WO2005103013A1 Therapeutic agent for nonviral hepatitis
11/03/2005WO2005103012A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof
11/03/2005WO2005103011A1 Processes for preparing substituted n-aryl-n’-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
11/03/2005WO2005103009A1 Alkaloid compounds and their use as anti-malarial drugs
11/03/2005WO2005103008A1 Alkaloid compounds and their use as anti-malarial drugs
11/03/2005WO2005103007A1 Crystalline 6-ethoxy-2,2,4-trimethyl-tetrahydroquinoline and a method for the production thereof
11/03/2005WO2005103003A2 Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
11/03/2005WO2005102999A2 Crystalline forms of fexofenadine hydrochloride and processes for their preparation
11/03/2005WO2005102998A1 Novel androgens
11/03/2005WO2005102981A1 Novel compounds and medicinal use thereof
11/03/2005WO2005102455A1 Use of c-kit inhibitors for treating plasmodium related diseases
11/03/2005WO2005102411A2 A system with a sensor for perfusion management
11/03/2005WO2005102410A2 A system with a reservoir for perfusion management
11/03/2005WO2005102409A2 A system for perfusion management
11/03/2005WO2005102408A2 A telescoping perfusion management system
11/03/2005WO2005102393A1 Patch for external use with elevated content of absorption promoter in pressure-sensitive adhesive base
11/03/2005WO2005102392A2 Combinations for treating hiv infection
11/03/2005WO2005102391A1 Combinations for the treatment of aids or hiv infections
11/03/2005WO2005102390A2 Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
11/03/2005WO2005102389A2 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
11/03/2005WO2005102388A1 Novel blt2-mediated disease, and blt2 binding agent and compound
11/03/2005WO2005102381A1 Bone densifying agent characterized by use of cathepsin k inhibitor with pth
11/03/2005WO2005102380A2 Methods of inhibiting inflammation
11/03/2005WO2005102378A2 Modular furniture system
11/03/2005WO2005102372A1 Compositions for correcting age related changes of a human endocrine system and methods for producing a pharmaceutical form bases on said compositions
11/03/2005WO2005102367A2 Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
11/03/2005WO2005102366A2 Lithium combinations, and uses related thereto
11/03/2005WO2005102365A1 Neurotransmission switching material
11/03/2005WO2005102364A1 Compressed pharmaceutical compositions comprising peg and electrolytes
11/03/2005WO2005102363A2 Methods of promoting cartilage healing or cartilage integration
11/03/2005WO2005102362A1 Use of chondroitin sulphate e (cs-e ) for the treatment diseases or conditions related to collagen fibril formation.
11/03/2005WO2005102361A2 Method of producing microcrystalline cellulose containing compositions
11/03/2005WO2005102360A1 Synergistic composition for inhibiting a human immunodeficiency virus
11/03/2005WO2005102359A1 Liposomal formulations of anthracycline agents and cytidine analogs
11/03/2005WO2005102358A2 Silicone-substituted cox-2 selective inhibitors
11/03/2005WO2005102357A1 Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
11/03/2005WO2005102356A1 Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
11/03/2005WO2005102355A1 METHODS OF TREATING VARIOUS VITAMIN D METABOLISM CONDITIONS WITH 1α-HYDROXYVITAMIN D2
11/03/2005WO2005102354A1 Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
11/03/2005WO2005102353A1 Supportive treatment of liver disease
1 ... 4478 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 ... 7860